サインイン 無料でサインアップします。

Akari Therapeutics Plcの資本の返還

Akari Therapeutics Plcの資本の返還は何ですか。

Akari Therapeutics Plcの資本の返還は-365.06%です。

資本の返還の定義は何ですか。



株主資本利益率は、株主資本の簿価との関係で事業の収益性の尺度です。これは、会計年度純利益を株主資本合計で除算することによって計算されます。

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

NASDAQのセクタHealth Careにおける資本の返還の企業と比べるAkari Therapeutics Plc

Akari Therapeutics Plcは何をしますか。

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.

Akari Therapeutics Plcと類似の資本の返還